Prøve GULL - Gratis

Innovation – The next frontier

Express Pharma

|

October 2020

Alok Ghosh, Ex-President - Global Technical Operations, Lupin, underscores the importance of creating a conducive environment to foster innovation in India’s life sciences sector to ensure its continuous progress

- Alok Ghosh

Innovation – The next frontier

The USFDA recently is-sued a guideline titled product Launch Notification under Section 506I. The guideline instructs companies to let the USFDA know if a product is not launched even after 180 days of getting approval. USFDA felt the need to issue this guideline on product launch since data shows that only about 40 per cent of generic products are getting launched after USFDA approval within a year. This means about 60 per cent of products are not getting launched after USFDA approval even after a year. The data also shows that even after five years about 30 per cent of products are not getting launched. Pharma companies spend a lot of money on development, bio studies, filing of product and pay GDUFA fees. Then, why are the products not launched even after approval? The answer is that there are way too many competitors marketing the same product thereby reducing the scope of marketing or the cost of the product is prohibitive to selling the product at a competitive price.

Essentially two developments have happened in the last couple of years:

1. The USFDA stepped up approval of products by introducing GDUFA and inducted a lot of new inspectors/reviewers to clear the backlogs of approval. From a backlog of more than 36 months once, one can expect approval of new product now in 12-14 months if the quality of filing and data is acceptable. This helped in more generic products getting approval, throwing the US market into intense competition.

2. The market consolidated in the US and from about 10-12 buyers, today about 90 per cent of buying are controlled effectively by three buyers only, namely – Red Oak, Walgreen- Boots Alliance & McKesson. This means the buyers have now very high bargaining power bringing price pressure on marketed products. It is now a win-win situation for both, the government and consumers in the US.

FLERE HISTORIER FRA Express Pharma

Express Pharma

Express Pharma

Speed and flexibility play a critical role in how we compete with larger global players

Kriti Jajoo, VP-BD and Strategy, Shriji Polymers, as the next-gen leader, speaks on how the company is evolving with a leadership approach that balances technology, sustainability, and customer-centricity to create long-term value, in an interview with Express Pharma

time to read

6 mins

January 2026

Express Pharma

Express Pharma

Vizag rising: Shaping India's pharma future

At the Vizag Pharma Summit 2025, hosted by Express Pharma, industry leaders discussed how quality, R&D, compliance, and emerging technologies are driving India's next phase of pharma growth

time to read

9 mins

January 2026

Express Pharma

Express Pharma

Future of pharma: Trends, challenges & AI

Industry experts discussed how Al is transforming pharmaceutical R&D, highlighting both the promise and the practical limitations of current technologies

time to read

2 mins

January 2026

Express Pharma

Express Pharma

Gandhi Automations presents multi-composites, high-performance door PRIME NEO for clean environments

When it comes to pharmaceutical facilities and laboratories, clean rooms' hygiene and protection from environmental contamination are the most important factors to consider.

time to read

1 mins

January 2026

Express Pharma

Express Pharma

Can Indian biosimilars and generics restate accessibility in global underserved markets?

Hari Kiran Chereddi, MD & CEO - HRV Pharma & NHG Pharma highlights that India's success in generics is no longer enough, as the world now demands advanced biologics, biosimilars, and personalised medicines. He further emphasises on the need for stronger regulation, innovation, and investment so India can lead in next-generation therapies and expand global access to cutting-edge healthcare

time to read

3 mins

January 2026

Express Pharma

Express Pharma

The next wave of growth will belong not to the fastest manufacturers but to the most innovative problem-solvers

As India moves into 2026, industry experts state that the next phase of growth in pharmaceuticals will depend on strengthening formulation R&D, building a skilled and adaptable workforce, and closing gaps between academic research and industry needs.

time to read

6 mins

January 2026

Express Pharma

Express Pharma

Results win customers. Leadership discipline keeps them

Drawing themes from his new book The Dual Mandate in B2B - Driving Results. Shaping Culture, Mohan Joshi - Global C-Suite Partner & Former President, SCHOTT India, discusses leadership systems, alignment, and execution in conversation with Neha Aathavale.

time to read

3 mins

January 2026

Express Pharma

Express Pharma

INDIA'S INNOVATION JOURNEY FROM PROMISE TO PROOF

India's pharma ecosystem is ready to embrace stronger science and bolder ideas. Turning early breakthroughs into scalable, sustainable innovation remains the challenge

time to read

8 mins

January 2026

Express Pharma

Express Pharma

PRUV® -The original Sodium Stearyl Fumarate

JRS Pharma's PRUV® is the original sodium stearyl fumarate (SSF) introduced in the market over 20 years ago

time to read

5 mins

January 2026

Express Pharma

Express Pharma

Odisha's pharma pitch

The inaugural Odisha Pharma Summit 2025 delivered strong early signals of intent, positioning the state as an upcoming destination for PLI-triggered expansions, to complement existing pharma hubs. As Hemant Sharma, ACS Industry Dept and I&PR Dept, Govt of Odisha puts it, the aim is to “become a good, viable second option.” How fast can the eastern newcomer catch up and become India's next life sciences hub, asks Viveka Roychowdhury

time to read

5 mins

January 2026

Translate

Share

-
+

Change font size